ATIM-03. TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA: A PHASE 2 STUDY

Despite aggressive treatment with surgery, radiation therapy and chemotherapy, the median overall survival for recurrent glioblastoma (rGBM) averages 25 weeks. Our prior experience in 8 bevacizumab-refractory GBM patients initially treated with TTFields monotherapy and re-challenged with bevacizumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Tran, David, Ghiaseddin, Ashley, Campian, Jian, Staal, Stephen, Warren, Sonisha, Allen, Anne, Sampson, Deborah, Greene, Valerie, Ansstas, George
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216115/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados